Health and Fitness Health and Fitness
Wed, October 17, 2012
Tue, October 16, 2012

Where We Are Headed - New Outlook on Stemcells, Inc. and Repligen Corporation


Published on 2012-10-16 05:18:38 - Market Wire
  Print publication without navigation


October 16, 2012 08:08 ET

Where We Are Headed - New Outlook on Stemcells, Inc. and Repligen Corporation

JAKARTA, INDONESIA--(Marketwire - Oct 16, 2012) - Moments ago, [ NationalTradersAssociation.org ] introduced new coverage of Stemcells, Inc. (NASDAQ: [ STEM ]) and Repligen Corporation (NASDAQ: [ RGEN ]). Full outlook, analysis and consensus opinion is available to readers via the links below.

[ www.NationalTradersAssociation.org/r/gov/7e25_STEM ]
[ www.NationalTradersAssociation.org/r/gov/533f_RGEN ]

The consistent delivery of accurate analyses relies solely on two factors, namely: market awareness and industry insight. Recent market drivers include newly released third estimates of 1.3% for US second-quarter 2012 GDP growth notably below expectations of 1.7% (2nd estimate), smaller gains in non-residential construction as well as a slower build in business inventories and the recent rise in personal consumer expenditure (PCE) by 0.5% in August 2012 following July's 0.4% increase. When it comes to discovering the right edge at the right time, all these factors play into effect. For a deeper understanding of the mechanics behind these events and how it can affect your portfolio, please refer to our email newsletter delivered to your inbox.

National Traders Association is releasing new coverage on Stemcells, Inc. for its current position within the health care sector. StemCells, Inc. (StemCells) is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. A copy of this report featuring Stemcells, Inc. (NASDAQ: [ STEM ]) is available at: [ www.NationalTradersAssociation.org/r/gov/7e25_STEM ].

National Traders Association has released research on Repligen Corporation for its changing role within the health care sector. Repligen Corporation (Repligen) is a supplier of critical products used to manufacture biologic drugs. The Company manufactures Protein A for life science companies under long term supply agreements and also sell products directly to end users for use in their manufacturing processes. To access the full research report on Repligen Corporation (NASDAQ: [ RGEN ]) we welcome investors to visit: [ www.NationalTradersAssociation.org/r/gov/533f_RGEN ].

Consider National Traders Association
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop -- long before they become the next top news on major financial networks.


Contributing Sources